



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

November 20, 2023

Dr. David Angulo
Chief Executive Officer
SCYNEXIS INC
1 Evertrust Plaza, 13th Floor
Jersey City, NJ 07302-6548

Re: SCYNEXIS INC
Registration Statement on Form S-3
Filed November 13, 2023
File No. 333-275513

Dear Dr. David Angulo:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Cindy Polynice at 202-551-8707 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Matthew Hemington, Esq.